iTRAQ-Based Quantitative Proteomics Revealing the Therapeutic Mechanism of a Medicinal and Edible Formula YH0618 in Reducing Doxorubicin-Induced Alopecia by Targeting Keratins and TGF-β/Smad3 Pathway

    June 2024 in “ Heliyon
    Renkai Li, Mingxia Chen, Danxi Yan, Liang Chen, Man-di Lin, Bohui Deng, Likai Zhuang, Fei Gao, Gph Leung, Jieshu You
    Image of study
    TLDR YH0618 helps reduce chemotherapy-induced hair loss by targeting specific proteins and pathways.
    The study investigates the therapeutic mechanism of the medicinal and edible formula YH0618 in reducing doxorubicin-induced alopecia using iTRAQ-based quantitative proteomics. Researchers identified 3894 proteins, with significant changes in keratins (Krt33a, Krt33b, Krt34, Krt81) and the TGF-β/Smad3 pathway due to doxorubicin treatment. YH0618 administration reversed these effects, reducing hair loss and promoting hair regrowth in mice. The findings suggest that YH0618 mitigates hair loss by modulating energy metabolism, hormone control, and inflammatory response, providing a foundation for future research on treatments for chemotherapy-induced alopecia.
    Discuss this study in the Community →

    Research cited in this study

    13 / 13 results

    Related Community Posts Join

    0 / 0 results
    — no results

    Similar Research

    5 / 9 results